RecruitingNCT04985058
Real-world Data in Patients With Breast Cancer Treated With Abemaciclib
Real-world Clinical Outcome and Toxicity Data in Patients With Breast Cancer Treated With Abemaciclib Combined With Endocrine Therapy: the Experience of the Hellenic Cooperative Oncology Group
Sponsor
Hellenic Cooperative Oncology Group
Enrollment
108 participants
Start Date
Oct 6, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Histologically confirmed HR-positive, HER2-negative breast cancer
- Treated at Hellenic Cooperative Oncology Group (HeCOG)-affiliated departments of oncology
- years or older
- Any menopausal status
- Treatment with abemaciclib in combination with endocrine therapy
- Any endocrine therapy
- At least two months of treatment with abemaciclib
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04985058
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location